MedPath

Dedicated Trialist Nurse Navigators Help Advance Cancer Therapy Into Accelerated Approval

Sally Lau, MD, discusses her role in the DeLLphi-304 trial, focusing on the accelerated approval of Imdelltra for relapsed small-cell lung cancer. She highlights the importance of nurse navigators and diversity grants in supporting patient enrollment and retention in trials, emphasizing the need for early involvement and responsive sponsors. Lau's passion for clinical trials stems from witnessing direct patient benefits and innovative treatment approaches.


Reference News

Dedicated Trialist Nurse Navigators Help Advance Cancer Therapy Into Accelerated Approval

Sally Lau, MD, discusses her role in the DeLLphi-304 trial, focusing on the accelerated approval of Imdelltra for relapsed small-cell lung cancer. She highlights the importance of nurse navigators and diversity grants in supporting patient enrollment and retention in trials, emphasizing the need for early involvement and responsive sponsors. Lau's passion for clinical trials stems from witnessing direct patient benefits and innovative treatment approaches.

© Copyright 2025. All Rights Reserved by MedPath